Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 2.7x - 2.9x | 2.8x |
| Historical Pb Multiple | -6.7x - 12.7x | 3.6x |
| Fair Value | $0.93 - $1.03 | $0.98 |
| Upside | -25.3% - -17.4% | -21.3% |
| Benchmarks | - | Full Ticker |
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Geron Corporation | - | NasdaqGS:GERN |
| Trevena, Inc. | - | OTCPK:TRVN |
| Taysha Gene Therapies, Inc. | - | NasdaqGS:TSHA |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| DYAI | ONCO | CRDF | GERN | TRVN | TSHA | |||
| NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | OTCPK:TRVN | NasdaqGS:TSHA | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 14.5% | -182.3% | -9.6% | 5.2% | -10.6% | 20.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -404.2% | -19098.5% | -7594.3% | -23982.0% | -19680.3% | -1668.2% | ||
| Prior Fiscal Year | -234.4% | NA | -8496.9% | -77690.7% | 12839.7% | -722.1% | ||
| Latest Fiscal Year | -166.2% | -63986.5% | -6655.2% | -226.7% | -1289.2% | -1071.6% | ||
| Latest Twelve Months | -166.2% | -2758.7% | -6655.2% | -226.7% | -6233.7% | -1071.6% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -64.3% | -167.8% | -54.9% | -70.4% | -273.1% | -417.0% | ||
| Prior Fiscal Year | -80.1% | -113.4% | -47.1% | -112.3% | -133.8% | -294.0% | ||
| Latest Twelve Months | -139.2% | -233.8% | -59.5% | -66.1% | -1918.1% | -121.9% | ||
| Next Fiscal Year | 981.3% | 159.0% | -110.5% | -35.8% | 112.4% | -668.3% | ||
| Two Fiscal Years Forward | 82.9% | 72.2% | 590.2% | -9.9% | 17.5% | 124.2% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 10.7x | 0.3x | 240.6x | 11.4x | 1.8x | 30.6x | ||
| Price / LTM EPS | -6.4x | 0.0x | -3.6x | -5.0x | 0.0x | -2.9x | ||
| Price / Book | 15.1x | 0.0x | 2.0x | 3.1x | 0.0x | 3.6x | ||
| Price / Fwd Book | -10.0x | 0.0x | 6.9x | 4.5x | 0.0x | -6.6x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.0x | 2.0x | 15.1x | |||||
| Historical P/B Ratio | -6.7x | 3.6x | 12.7x | |||||
| Selected P/B Multiple | 2.7x | 2.8x | 2.9x | |||||
| (x) Book Value | 72 | 72 | 72 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | ONCO | CRDF | GERN | TRVN | TSHA | |
| Value of Common Equity | 37 | 1 | 164 | 879 | 1 | 255 | |
| (/) Shares Outstanding | 30.1 | 8.3 | 66.5 | 636.9 | 0.9 | 205.0 | |
| Implied Stock Price | 1.24 | 0.06 | 2.47 | 1.38 | 1.13 | 1.25 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.24 | 0.06 | 2.47 | 1.38 | 1.13 | 1.25 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |